Table 1.
Characteristics of HR+/HER2− patients.
| Number of Patients | Percentage | |
|---|---|---|
| 1738 | 100% | |
| Age | 60.1 ± 12.3 | |
| Menopausal status | ||
| Premenopausal | 491 | 28.3 |
| Postmenopausal | 1203 | 69.2 |
| Male | 3 | 0.2 |
| n/a | 41 | 2.4 |
| Histology | ||
| NST | 1360 | 78.3 |
| ILC | 277 | 15.9 |
| Other | 100 | 5.8 |
| n/a | 1 | 0.1 |
| Grading | ||
| 1 | 214 | 12.3 |
| 2 | 1247 | 71.7 |
| 3 | 275 | 15.8 |
| n/a | 2 | 0.1 |
| T-stage * | ||
| 0 | 43 | 2.5 |
| 1 | 1041 | 59.9 |
| 2 | 540 | 31.1 |
| 3 | 80 | 4.6 |
| 4 | 34 | 2.0 |
| N-stage * | ||
| 0 | 1195 | 68.8 |
| 1 | 415 | 23.9 |
| 2 | 89 | 5.1 |
| 3 | 38 | 2.2 |
| X | 1 | 0.1 |
| ER status | ||
| + | 1729 | 99.5 |
| − | 9 | 0.5 |
| PR status | ||
| + | 1447 | 83.3 |
| − | 291 | 16.7 |
| HER2 status | ||
| + | 0 | 0.0 |
| − | 1738 | 100.0 |
| Ki67 | ||
| ≥20% | 580 | 33.4 |
| <20% | 1158 | 66.6 |
| Chemotherapy | ||
| Neoadjuvant | 146 | 8.4 |
| Adjuvant | 313 | 18.0 |
| None | 1279 | 73.6 |
* T and N stages were assessed after surgery. NST, non-special type; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; n/a, not available.